Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
MRK

MRK - Merck & Co Inc Stock Price, Fair Value and News

$106.88-1.04 (-0.96%)
Market Closed

66/100

MRK

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

66/100

MRK

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$122.57

Target 3M

$111.64

Target 6M

$115.21

MRK Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MRK Price Action

Last 7 days

-3.8%

Last 30 days

0.2%

Last 90 days

23.9%

Trailing 12 Months

9.7%

MRK RSI Chart

MRK Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MRK Valuation

Market Cap

265.3B

Price/Earnings (Trailing)

13.94

Price/Sales (Trailing)

4.13

EV/EBITDA

12.02

Price/Free Cashflow

20.33

MRK Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$122.57

Target 3M

$111.64

Target 6M

$115.21

MRK Fundamentals

MRK Revenue

Revenue (TTM)

64.2B

Rev. Growth (Yr)

3.72%

Rev. Growth (Qtr)

9.3%

MRK Earnings

Earnings (TTM)

19.0B

Earnings Growth (Yr)

83.24%

Earnings Growth (Qtr)

30.68%

MRK Profitability

EBT Margin

33.96%

Return on Equity

36.71%

Return on Assets

14.69%

Free Cashflow Yield

4.92%

MRK Investor Care

Dividend Yield

3.7%

Dividend/Share (TTM)

3.12

Buy Backs (1Y)

1.88%

Diluted EPS (TTM)

7.58

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202563.9B63.6B64.2B0
202461.4B62.5B63.2B64.2B
202357.9B58.3B59.3B60.1B
202254.0B57.2B59.0B59.3B
202141.0B43.0B45.2B48.7B
202040.4B38.0B36.5B42.4B
201943.1B44.4B46.0B39.1B
201840.7B41.3B41.7B42.3B
201739.9B40.0B39.8B40.1B
201639.4B39.4B39.9B39.8B
201541.4B40.2B39.8B39.5B
201443.6B43.5B43.1B42.2B
201346.2B44.9B44.5B44.0B
201248.2B48.4B47.8B47.3B
201146.1B47.0B47.8B48.0B
201000046.0B
Get all data in R, Python etc through our Historical Stock Data APIs

About Merck & Co Inc

MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
 CEO
 WEBSITEmerck.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers General
 EMPLOYEES65535

Merck & Co Inc Frequently Asked Questions

MRK is the stock ticker symbol of Merck & Co Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Merck & Co Inc is 265.28 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check MRK's fair value in chart for subscribers.

The fair value guage provides a quick view whether MRK is over valued or under valued. Whether Merck & Co Inc is cheap or expensive depends on the assumptions which impact Merck & Co Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRK.

As of Wed Jan 28 2026, MRK's PE ratio (Price to Earnings) is 13.94 and Price to Sales (PS) ratio is 4.13. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRK PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Merck & Co Inc has provided 0.083 (multiply by 100 for percentage) rate of return.